filgotinib - Robuta Search

https://www.gilead.com/news/news-details/2020/filgotinib-demonstrates-durable-efficacy-and-consistent-safety-profile-at-52-weeks-in-finch-1-and-3-studies-in-rheumatoid-arthritis Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3... Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis https://www.gilead.com/news/news-details/2020/gilead-and-galapagos-announce-positive-topline-results-of-phase-2b3-trial-of-filgotinib-in-moderately-to-severely-active-ulcerative-colitis Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in... Gilead and Galapagos Announce Positive Topline Results of Phase 2b3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis https://www.benzinga.com/general/biotech/21/10/23236881/galapagos-filgotinib-shows-clinical-benefit-in-ulcerative-colitis-non-responding-patients Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients -... ulcerative colitis galapagos filgotinib shows clinical https://www.gilead.com/news/news-details/2019/gilead-and-galapagos-to-present-latest-data-on-filgotinib-at-the-annual-european-congress-of-rheumatology-eular-2019 Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of... Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology EULAR 2019 https://www.fiercebiotech.com/biotech/gilead-s-filgotinib-fails-midphase-tests-lupus-sjogren-s Gilead's filgotinib fails midphase tests in lupus, Sjogren's | Fierce Biotech Oct 25, 2019 - A clutch of Gilead drugs including filgotinib have failed to move the needle in midphase clinical trials of cutaneous lupus and Sjogren's syndrome patients. gilead filgotinib fails midphase https://investingnews.com/daily/life-science-investing/biotech-investing/gilead-galapagos-tortuga-phase-2-study-filgotinib-ankylosing-spondylitis-achieves-primary-endpoint/ Gilead and Galapagos Announce Tortuga Phase 2 Study of Filgotinib in Ankylosing Spondylitis... Jan 4, 2026 - Gilead Sciences (NASDAQ:GILD) and Galapagos (NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an... phase 2 study https://www.gilead.com/news/news-details/2020/gilead-receives-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely... Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis complete response letter https://www.gilead.com/news/news-details/2018/gilead-and-galapagos-announce-results-with-filgotinib-in-the-phase-2-equator-study-in-psoriatic-arthritis-and-progression-into-phase-3-for-the-selection-study-in-ulcerative-colitis Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic... Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study... https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL3301607 Compound: FILGOTINIB (CHEMBL3301607) - ChEMBL Report card for Compound FILGOTINIB (CHEMBL3301607). C21H23N5O3S, Small molecule, Filgotinib, FILGOTINIB, G-146034, G146034, GLPG-0634, GLPG0634, GS-6034 FREE... compound filgotinib chembl https://www.biospace.com/press-releases/filgotinib-shows-positive-topline-results-across-full-spectrum-of-axial-spondyloarthritis-in-olinguito-phase-3-study Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in... https://www.gilead.com/news/news-details/2016/galapagos-and-gilead-complete-closing-of-their-global-collaboration-for-filgotinib Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib Galapagos and Gilead Complete Closing of Their Global Collaboration for Filgotinib global collaboration galapagos gilead complete closing